CN108771242A - A kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application - Google Patents
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application Download PDFInfo
- Publication number
- CN108771242A CN108771242A CN201810632932.6A CN201810632932A CN108771242A CN 108771242 A CN108771242 A CN 108771242A CN 201810632932 A CN201810632932 A CN 201810632932A CN 108771242 A CN108771242 A CN 108771242A
- Authority
- CN
- China
- Prior art keywords
- coronoid process
- capsule bacterium
- process dissipate
- dissipate capsule
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 241000894006 Bacteria Species 0.000 title claims abstract description 114
- 230000008569 process Effects 0.000 title claims abstract description 108
- 239000002775 capsule Substances 0.000 title claims abstract description 107
- 238000000855 fermentation Methods 0.000 title claims abstract description 91
- 230000004151 fermentation Effects 0.000 title claims abstract description 91
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 244000269722 Thea sinensis Species 0.000 claims abstract description 62
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 239000000725 suspension Substances 0.000 claims abstract description 32
- 238000002386 leaching Methods 0.000 claims abstract description 22
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 12
- 239000000654 additive Substances 0.000 claims abstract description 11
- 230000000996 additive effect Effects 0.000 claims abstract description 11
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract 2
- 235000013616 tea Nutrition 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 15
- 239000008223 sterile water Substances 0.000 claims description 12
- 241001205401 Aspergillus cristatus Species 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 235000020279 black tea Nutrition 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229920001817 Agar Polymers 0.000 claims description 7
- 239000008272 agar Substances 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000003643 water by type Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 235000006468 Thea sinensis Nutrition 0.000 claims description 6
- 239000012531 culture fluid Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000010355 oscillation Effects 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000036284 oxygen consumption Effects 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 230000033228 biological regulation Effects 0.000 abstract description 6
- 230000001900 immune effect Effects 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 235000013373 food additive Nutrition 0.000 abstract description 4
- 239000002778 food additive Substances 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000005445 natural material Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241001247821 Ziziphus Species 0.000 description 8
- 239000011449 brick Substances 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 235000015468 Lycium chinense Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 229940062044 oxygen 40 % Drugs 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- -1 atherosclerosis Chemical class 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229930184989 physalin Natural products 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to biological chemical fields more particularly to a kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application.Invention is by preparing tea leaching liquor, preparing fermentation culture, prepare coronoid process dissipate capsule bacterium suspension, coronoid process dissipate capsule bacterium liquid fermentation and produce five steps of function and service object, the pure natural substances such as ordinary tea leaves and matrimony vine, jujube, American Ginseng are prepared into fermentation culture as additive, coronoid process dissipate capsule bacterium is fermented using the culture solution, functional complex is made, the compound taste faint scent, contained nutritional ingredient is various, without any food additives, and have both the double effects of immunological regulation and reducing blood lipid.
Description
Technical field
The invention belongs to biological chemical field more particularly to a kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation sides
Method and application.
Background technology
In daily life, matrimony vine, jujube etc., which are often used in, makes tea or impregnates medicinal liquor.Research is found in matrimony vine
Containing there are many amino acid, and containing special nutrient compositions such as glycine betaine, zeaxanthine, physalins, have extraordinary
Health-care efficacy.The multiple efficacies of matrimony vine include mainly immunological regulation, anti-aging, antitumor, antifatigue, Antiradiation injury, adjusting
Blood fat, protection reproductive system, improves eyesight, improves respiratory tract disease resistance, beautifying face and moistering lotion hypoglycemic, blood pressure lowering, moistens flesh
Skin, protection liver, enhancing hematopoiesis function etc..Jujube can improve the immunity of the human body, and inhibit growth of cancer cells, contained therein
Rutin can soften blood vessel.American Ginseng can improve immunity of organisms as qi-tonifying health-care first choice medicinal material, inhibit growth of cancer cells；
Saponin in American Ginseng can effectively enhance central nervous system function；The long American Ginseng that takes can protect cardiovascular system, promote
Blood vigor；It has the function of reducing blood glucose, adjusts insulin secretion simultaneously.
Tealeaves is a kind of plant rich in polyphenols, and contained classes of compounds up to more than 700 is planted.And with tealeaves
Extract liquor, concentration powder, tea powder etc., which are the tea beverage mainly to process raw material, not only has the refreshing taste of tealeaves, and more containing tea
The active ingredients such as phenol, catechin, caffeine.Have result of study and show that the active ingredient in tealeaves can directly remove free radical,
Avoid oxidative damage.Therefore, these active ingredients may act on many diseases related with free radical such as atherosclerosis, sugar
Disease, organism aging process etc. are urinated, has and prevents the multiple pharmacological effects such as cardiovascular and cerebrovascular disease, anti-bacteria and anti-virus.
In the basic teas of six major class of China, Fu-brick tea is one kind of compressed black tea, is original with Dark Green Tea or thick old green tea
Material, the manufactured reprocessing tea by compacting process.In Fu-brick tea " floating " technique, there is a kind of dominant microflora, that is, coronoid process
Bulk bacteria can promote growth to breed by controlling external condition, a large amount of macroscopic to be born on Fu-brick tea surface
Golden yellow cleistothecium is commonly called as " golden flower ".Due to the presence of coronoid process dissipate capsule bacterium, the unique quality of Fu-brick tea and flavor are imparted.Cause
This, people often judge Fu-brick tea quality with the quality and quantity of " golden flower ".Research finds that coronoid process dissipates and wraps up in why bacterium has so
More effects is attributed to the fact that it and meets the growth and development of itself in growth course, can absorb the nutriment in tealeaves,
While utilizing and converting these nutriments, many metabolites are secreted, such as antioxidation class metabolite, lipid-loweringing class
Metabolite, enzyme metabolite, fragrance class metabolite, amino acids metabolite, antibacterial, antitumor class metabolite
Deng.By taking antibacterial, antitumor class metabolite as an example, in Fu-brick tea " floating " technique, the raised growth of coronoid process dissipate capsule bacterium is bred
It can obviously inhibit and other bacteriums and mould is interfered significantly to grow.Fourth is graceful et al. to find coronoid process in 2012 by bacteriostatic experiment
Bulk bacteria liquid fermentation liquid has bacteriostasis to Escherichia coli, staphylococcus aureus.(coronoid process dissipate capsule bacterium is extracellular more by Deng Fangming
Sugared bioactivity high throughput screening assay, 2007) etc. inhibition of the Techniques of Extracellular Polysaccharide of Eurotium cristatum to tumor model cell is had studied
As a result effect confirms that Techniques of Extracellular Polysaccharide of Eurotium cristatum has Anti-tumor angiogenesis.Therefore, the metabolic activity of coronoid process dissipate capsule bacterium is not
Only promote the various composition in tealeaves that apparent variation occurs, largely form the unique color of Fu-brick tea,
And creating it is beneficial to magical effect of health.Exactly these unique vital movements, just so that coronoid process dissipate capsule bacterium
Research and development have very important significance.When solid culture coronoid process dissipate capsule bacterium, although its growing way is vigorous, it is not appropriate for
Large-scale production；When liquid fermentation technology cultivates coronoid process dissipate capsule bacterium, not only with short production cycle, at low cost, yield is big, and
And when Liquid Culture coronoid process dissipate capsule bacterium mycelium, thalli growth metabolism is more active, is more advantageous to the accumulation of active constituent.Therefore,
Large-scale culture and the production of coronoid process dissipate capsule bacterium may be implemented using modern liquid fermentation technology.
Currently, Lv Jia manger's (Primary Study of coronoid process dissipate capsule bacterium liquid fermentation production lipid-loweringing substance, 2014) etc. dissipates coronoid process
Capsule fermented liquid is studied, it was demonstrated that contains lipid-loweringing ingredient Lovastatin in coronoid process dissipate capsule bacterium liquid fermentation extracting solution, respectively
For acid Lovastatin and ester formula Lovastatin.Separately have some researchs confirm coronoid process dissipate capsule bacterium mycelium equally and have reducing blood lipid,
Hypoglycemic and antitumor effect.The above result of study provides adequately for the relevant health products exploitation of coronoid process dissipate capsule bacterium fermentation
Theoretical foundation.Currently, the coronoid process dissipate capsule bacterium fermentation generally existing medium component largely studied is simple, relevant healthcare product effect
Insufficient and single defect.
Invention content
It is compound that an object of the present invention is to provide a kind of coronoid process dissipate capsule bacterium Fermentation Function that medium nutrient content is various
Object and its preparation method and application, the second object of the present invention is to provide a kind of coronoid process dissipate capsule bacterium that health-care efficacy is various fermentation work(
Energy compound and its preparation method and application.
To achieve the above object, the present invention adopts the following technical scheme that realize：
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method, includes the following steps
Step 1：Prepare tea leaching liquor
Tealeaves and active additive, water are added in water：Tealeaves：The weight ratio of active additive is 100: 4-8: 0.5-3,
20-60min is extracted under the conditions of 60-120 DEG C of constant temperature, is filtered to remove tea grounds up to tea leaching liquor；
Step 2：Prepare fermentation culture
A kind of tea leaching liquor obtained of step and carbon source nutriment are mixed in the ratio that volume mass ratio is 100: 4-8
Prepare, the pH value of solution of configuration is 5.0-5.5, is then 115-121 DEG C in temperature condition, pressure under the conditions of 0.1-0.15MPa,
Persistently sterilizing 20-30min is up to fermentation culture；
Step 3：Prepare coronoid process dissipate capsule bacterium suspension
It is coated on the strain of coronoid process dissipate capsule bacterium on PDA agar mediums, under 28-30 DEG C of constant temperature, cultivates 4-6
Coronoid process dissipate capsule bacterium spore is scraped and is placed in equipped with sterile water then toward after being added 5-10ml sterile waters on solid medium by it
In container, then suspension is poured into oscillation container in sterile water upper surface, is placed in rotating speed by coronoid process dissipate capsule bacterium spore suspension
0.5-1h is vibrated for the shaking table of 150-300r/min, is made a concentration of 5 × 108-9×108Cfu/mL coronoid process dissipate capsule bacterium spores are outstanding
Liquid；
Step 4：Coronoid process dissipate capsule bacterium liquid fermentation
By eurotium cristatum spore suspension made from step 3, accesses according to the inoculum concentration of 5%-8% and be made by step 2
Aseptic culture fluid in, setting fermentation parameter be respectively：Rotating speed 100-500r/min, pH value 5.0-5.5, dissolved oxygen 20%-
40%, 28-30 DEG C of temperature cultivates 120-168h, stops hair when zymotic fluid color is not further added by red gorgeous transparent and hyphae length
Ferment；
Step 5：Produce function and service object
The zymotic fluid for collecting simultaneously four gained of concentration step goes moisture removal, detection wherein coronoid process dissipate capsule bacterium viable count to be not less than 1
×103Cfu/g is to get function and service object.
Active additive in the step one is that matrimony vine or one or more of jujube or American Ginseng mix.
The carbon source nutriment is sucrose or glucose.
Zymotic fluid in the step four is to be concentrated zymotic fluid using butterfly centrifugal machine.
The step four is concentrated into the 1/3-1/2 of original volume.
The tealeaves is the composition of black tea or one or more of green tea or black tea tea.
Fermentation in the step two is by the way of oxygen consumption fermentation.
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound, by a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method
It is made.
Dosage form made of the functional complex is solid pharmaceutical preparation, liquid preparation and gel preparation, wherein solid system
Agent is tablet or pulvis or capsule or pill or tincture or granule, and liquid preparation is suspension or emulsion.
A kind of application of coronoid process dissipate capsule bacterium Fermentation Function compound in drink or functional food.
The beneficial effects of the invention are as follows：
Invention is dissipated by preparing tea leaching liquor, preparing fermentation culture, preparation coronoid process dissipate capsule bacterium suspension, coronoid process
Capsule bacteria liquid ferments and produces five steps of function and service object, by the pure natural substances such as ordinary tea leaves and matrimony vine, jujube, American Ginseng
Fermentation culture is prepared as additive, coronoid process dissipate capsule bacterium is fermented using the culture solution, functional complex is made, this is compound
Object taste faint scent, contained nutritional ingredient is various, is free of any food additives, and has both the dual of immunological regulation and reducing blood lipid
Effect.
Description of the drawings
Present invention will be further explained below with reference to the attached drawings and examples.
Fig. 1 is preparation flow schematic diagram of the present invention.
Specific implementation mode
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation describes, it is clear that described embodiment is only a part of the embodiment of the present invention, instead of all the embodiments.Base
Embodiment in the present invention, those of ordinary skill in the art obtained without creative efforts it is all its
His embodiment, shall fall within the protection scope of the present invention.
Embodiment one：
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as shown in Figure 1, includes the following steps：
Step 1：Prepare tea leaching liquor
30kg water is weighed, 1.8kg black teas dry tea is added in the active additive of addition, water：Tealeaves：Active additive
Weight ratio is 100: 4-8: 0.5-3, and 20-60min is extracted under the conditions of 60-120 DEG C of constant temperature, is filtered to remove tea grounds and is extracted up to tea
Liquid；
Step 2：Prepare fermentation culture
A kind of tea leaching liquor obtained of step and carbon source nutriment are mixed in the ratio that volume mass ratio is 100: 4-8
It prepares, the pH value of solution of configuration is 5.0-5.5, is then 115-121 DEG C of temperature in temperature condition, pressure is in 0.1-0.15MPa items
Under part, the 20-30min that persistently sterilizes is up to fermentation culture；
Step 3：Prepare coronoid process dissipate capsule bacterium suspension
It is coated on the strain of coronoid process dissipate capsule bacterium on PDA agar mediums, under 28-30 DEG C of constant temperature, cultivates 4-6
Coronoid process dissipate capsule bacterium spore is scraped and is placed in equipped with sterile water then toward after being added 5-10ml sterile waters on solid medium by it
In container, then suspension is poured into oscillation container in sterile water upper surface, is placed in rotating speed by coronoid process dissipate capsule bacterium spore suspension
0.5-1h is vibrated for the shaking table of 150-300r/min, is made a concentration of 5 × 108-9×108Cfu/mL coronoid process dissipate capsule bacterium spores are outstanding
Liquid；
Step 4：Coronoid process dissipate capsule bacterium liquid fermentation
By eurotium cristatum spore suspension made from step 3, accesses according to the inoculum concentration of 5%-8% and be made by step 2
Aseptic culture fluid in, setting fermentation parameter be respectively：Rotating speed 100-500r/min, pH value 5.0-5.5, dissolved oxygen 20%-
40%, 28-30 DEG C of temperature cultivates 120-168h, stops hair when zymotic fluid color is not further added by red gorgeous transparent and hyphae length
Ferment；
Step 5：Produce function and service object
The zymotic fluid for collecting simultaneously four gained of concentration step goes moisture removal, detection wherein coronoid process dissipate capsule bacterium viable count to be not less than 1
×103Cfu/g is to get function and service object.
Zymotic fluid in the preferably described step three is to be concentrated zymotic fluid using butterfly centrifugal machine, and by zymotic fluid
It is concentrated into the 1/3-1/2 of original volume, can accelerate to concentrate speed in this way, improves concentration quality.
Fermentation preferably in step 2 is by the way of oxygen consumption fermentation.
In actual use, the tealeaves of common arbitrary kind can also be used to make tea leaching liquor in tealeaves.Coronoid process dissipates capsule
Bacterium needs carbon and nitrogen as nutriment during the fermentation, and carbon source nutriment is exactly to provide carbon for coronoid process dissipate capsule bacterium fermentation
Source.When specifically preparing fermentation culture, the strain of coronoid process dissipate capsule bacterium may be used following method separation, obtain：It is connect with sterile
Yellow cleistothecium on kind of ring picking Fu-brick tea block, is inoculated on the second culture medium, is cultivated under conditions of 30 DEG C of constant temperature, waits for bacterium
It falls when growing into animated period, with aseptic inoculation ring, a small amount of yellow cleistothecium of picking carries out the second culture medium flat plate scribing line, through 2
~3 the second culture medium flat plates scribing line preliminary purification bacterium；Single bacterium colony is chosen, is inoculated on the second culture medium of blank, is continued
It cultivates, the single bacterium colony on second culture medium is pure coronoid process dissipate capsule bacterium；Its colony characteristics is observed, and combines microscope detection
Volume morphing feature meets the grown form requirement of coronoid process dissipate capsule bacterium, with the appropriate coronoid process dissipate capsule bacterium of oese picking, is inoculated in
In 100mL sterile waters, 10-20min is shaken, uniform spore liquid is made, and carries out 10 times of incremental dilutions, is made 10-2-10-5It is dilute
The spore suspension for degree of releasing；The production method of PDA agar mediums used is the prior art.It ferments and is preferably in this programme
By the way of oxygen consumption fermentation so that fermentation process is easily enlarged production scale, product product quality is steady convenient for control and operation
Fixed and product is easy to extraction, refines.
The compound taste faint scent prepared using the method is free of any food additives, has both immunological regulation and drop blood
The double effects of fat.
Embodiment two：
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as shown in Figure 1, includes the following steps：
Step 1：Prepare tea leaching liquor
It weighs 30kg water, 2.0kg black tea dry teas is added, add 0.15kg dry wolfberry, soaked under the conditions of 120 DEG C of constant temperature
40min is carried, is filtered to remove tea grounds up to tea leaching liquor；
Step 2：Prepare fermentation culture
The ratio mixed preparing for being 100: 4 in volume mass ratio by a kind of tea leaching liquor obtained of step and glucose, matches
The pH value of solution set is 5.0-5.5, is then 115 DEG C of temperature in temperature condition, under the conditions of 0.12MPa, persistently sterilize pressure 20-
30min is up to fermentation culture；
Step 3：Prepare coronoid process dissipate capsule bacterium suspension
The strain of coronoid process dissipate capsule bacterium is coated on PDA agar mediums, under 28 DEG C of constant temperatures, culture 6 days, so
Afterwards toward after being added 10ml sterile waters on solid medium, coronoid process dissipate capsule bacterium spore is scraped and is placed in the container equipped with sterile water,
Then coronoid process dissipate capsule bacterium spore suspension pours into suspension in oscillation container in sterile water upper surface, it is 300r/ to be placed in rotating speed
The shaking table of min vibrates 0.5h, and it is 9 × 10 to control spore concentration by cell count8cfu/mL；
Step 4：Fermentation
By eurotium cristatum spore suspension made from step 3, the nothing made from step 2 is accessed according to 8% inoculum concentration
In bacteria culture fluid, setting fermentation parameter is respectively：Rotating speed 500r/min, pH value 5.5, dissolved oxygen 40%, 30 DEG C of temperature, culture
Stop fermentation when 168h；
Step 5：Produce function and service object
Zymotic fluid, the 1/2 of original volume is concentrated into using butterfly centrifugal machine by the zymotic fluid for collecting simultaneously four gained of concentration step,
Detection wherein coronoid process dissipate capsule bacterium viable count is not less than 1 × 103Cfu/g is to get function and service object.
In practical application, it is that tea leaching liquor effect made from black tea dry tea is best that tealeaves is added in step 1；It is added dry
The fruit of Chinese wolfberry makes function and service object obtained have better nutrition.When preparing fermentation culture, what carbon source nutriment used
It is glucose, sucrose can also be used.Any chemical addition agent is added during the compound prepared using the method, it is simultaneous
Have the double effects of immunological regulation and reducing blood lipid.
Embodiment three：
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as shown in Figure 1, includes the following steps：
Step 1：Prepare tea leaching liquor
30kg water is weighed, 2.4kg black teas dry tea and 0.5kg dry wolfberries, 0.5kg jujubes is added, in 100 DEG C of constant temperatures
Lower extraction 20min is filtered to remove tea grounds up to tea leaching liquor；
Step 2：Prepare fermentation culture
The ratio mixed preparing for being 100: 4 in volume mass ratio by a kind of tea leaching liquor obtained of step and glucose, matches
The pH value of solution set is 5.0, is then 121 DEG C of temperature in temperature condition, under the conditions of 0.15MPa, the 30min that persistently sterilizes is pressure
Obtain fermentation culture；
Step 3：Prepare coronoid process dissipate capsule bacterium suspension
The strain of coronoid process dissipate capsule bacterium is coated on PDA agar mediums, under 30 DEG C of constant temperatures, culture 4 days, so
Afterwards toward after being added 5ml sterile waters on solid medium, coronoid process dissipate capsule bacterium spore is scraped, is placed in the container equipped with sterile water,
Then coronoid process dissipate capsule bacterium spore suspension pours into suspension in oscillation container in sterile water upper surface, it is 200r/ to be placed in rotating speed
The shaking table of min vibrates 1h, and it is 5 × 10 to control spore concentration by cell count8cfu/mL；
Step 4：Coronoid process dissipate capsule bacterium liquid fermentation
By eurotium cristatum spore suspension made from step 3, the nothing made from step 2 is accessed according to 8% inoculum concentration
In bacteria culture fluid, setting fermentation parameter is respectively：Rotating speed 500r/min, pH value 5.0, dissolved oxygen 40%, 30 DEG C of temperature, culture
Stop fermentation when 144h；
Step 5：Produce function and service object
Zymotic fluid, the 1/3 of original volume is concentrated into using butterfly centrifugal machine by the zymotic fluid for collecting simultaneously four gained of concentration step,
Detection wherein coronoid process dissipate capsule bacterium viable count is not less than 1 × 103Cfu/g is to get function and service object.
In actual use, ordinary tea leaves may be used in tealeaves, if using black tea dry tea, effect can be more preferable.
Example IV：
A kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as shown in Figure 1, includes the following steps：
Step 1：Prepare tea leaching liquor
30kg water is weighed, 2.4kg black teas dry tea and 0.9kg dry wolfberries, 0.9kg jujubes, 80 DEG C of 0.5kg American Ginsengs is added
Lower extraction 60min is filtered to remove tea grounds up to tea leaching liquor；
Step 2：Prepare fermentation culture
The ratio mixed preparing for being 100: 8 in volume mass ratio by a kind of tea leaching liquor obtained of step and sucrose, configuration
PH value of solution be 5.5, then temperature condition be 115 DEG C of temperature, pressure under the conditions of 0.15MPa, persistently sterilize 25min to obtain the final product
Fermentation culture；
Step 3：Prepare coronoid process dissipate capsule bacterium suspension
The strain of coronoid process dissipate capsule bacterium is coated on PDA agar mediums, under 30 DEG C of constant temperatures, culture 6 days, so
Afterwards toward after being added 8ml sterile waters on solid medium, coronoid process dissipate capsule bacterium spore is scraped, is placed in the container equipped with sterile water,
Then coronoid process dissipate capsule bacterium spore suspension pours into suspension in oscillation container in sterile water upper surface, it is 500r/ to be placed in rotating speed
The shaking table of min vibrates 1h, and it is 9 × 10 to control spore concentration by cell count8cfu/mL；
Step 4：Coronoid process dissipate capsule bacterium liquid fermentation
By eurotium cristatum spore suspension made from step 3, the nothing made from step 2 is accessed according to 8% inoculum concentration
In bacteria culture fluid, setting fermentation parameter is respectively：Rotating speed 500r/min, pH value 5.5, dissolved oxygen 40%, 30 DEG C of temperature, culture
Stop fermentation when 168h；
Step 5：Produce function and service object
Zymotic fluid, the 1/3 of original volume is concentrated into using butterfly centrifugal machine by the zymotic fluid for collecting simultaneously four gained of concentration step,
Detection wherein coronoid process dissipate capsule bacterium viable count is not less than 1 × 103Cfu/g is to get function and service object.
In actual use, the preparation that matrimony vine, jujube and American Ginseng carry out millet paste culture medium is added so that obtained compound
Object nutrition is more abundant, comprehensive.
Embodiment five：
Unlike the embodiments above, dosage form made of the functional complex is solid pharmaceutical preparation, liquid preparation
And gel preparation, wherein solid pharmaceutical preparation is tablet or pulvis or capsule or pill or tincture or granule, liquid preparation are mixed
Suspension or emulsion.
A kind of preferably application of the coronoid process dissipate capsule bacterium Fermentation Function compound in drink or functional food.
In the specific implementation, dosage form made of functional complex is the agent such as solid pharmaceutical preparation, liquid preparation and gel preparation
Type, wherein solid pharmaceutical preparation are tablet or pulvis or capsule or pill or tincture or granule, and liquid preparation is suspension or breast
Agent meets the needs of different users, facilitates using under varying environment；By coronoid process dissipate capsule bacterium Fermentation Function compound application
In drink or functional food, the use scope of coronoid process dissipate capsule bacterium Fermentation Function compound is expanded, is suitble to different constitutions
People uses.
Embodiment six
Experiment of the coronoid process dissipate capsule bacterium Fermentation Function compound to the effect for reducing fat of hyperlipemia rat
Wistar rats 70, half male and half female, 150 ± 10g of weight are flat by weight with normal diet adaptable fed 1 week
It is divided into 7 groups, every group 10, be the work(that blank control group, model group, positive drug Simvastatin group, embodiment 4 are obtained respectively
The high, medium and low dosage group of energy property compound.Blank control group gavage physiological saline feeds normal diet；Model group gavage physiology salt
Water feeds high lipid food；Other 5 groups of corresponding given the test agent of difference gavage feed high lipid food.Tail blood is adopted in modeling 5 weeks first, is surveyed
Determine serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C) horizontal, TG, TC level are to determine whether to have been formed hyperlipemia model before and after comparing modeling.
Given the test agent dosage is shown in Table 1, and daily gavage 1 time, remaining time free water is freely eaten, lasting to feed administration 5
Week, the fasting 12h before experiment adopt tail blood, measure TG, TC, HDL-C, LDL-C level, test result in serum and are shown in Table 1.
Blood lipid level compares in 1 each group rat blood serum of table
Note：**P<0.01,*P<0.5VS Normal groups；▽▽P<0.01,▽P<0.5VS model groups, similarly hereinafter
Test result shows that TG, TC, LDL-C of model group rats serum are horizontal significantly raised, HDL-C levels under
Drop illustrates hyperlipemia rat modeling success.As can be seen from Table 1, compared with model group, positive drug simvastatin group totality
Lipid-lowering effect is best, level of the high dose group lipid-lowering effect close to positive drug group made from embodiment 4.In, the TG of low dose group,
TC values also decrease, but lipid-lowering effect is inferior to high dose group, have dose-dependence.In addition, the drop with ordinary tea leaves group
Fat effect is compared, and the lipid-lowering effect of high dose group made from embodiment 4 becomes apparent from, and dosage is (big well below the former
About 9%).
The above result shows that the lipid-lowering effect of the liquid fermentation coronoid process dissipate capsule bacterium functional complex of the present invention is apparent.
Embodiment seven
Experiment of the coronoid process dissipate capsule bacterium Fermentation Function compound to the effect of hypoimmunity mouse
Everyone (pressing 60kg batheroom scales) daily recommended intake is 3g, and it is 0.05g/ to be converted into daily kg body weight dosage
Kg.b.w, presses 5 times of human body recommended intake, 10 times, 25 times of basic, normal, high three dosage groups of design respectively, i.e., 0.25,0.5,
1.25g/kg.b.w.The test basis of strengthen immunity function be according to《Health food is examined and assessment technique specification》(2003
Year version) it carries out.Experiment uses cleaning grade ICR mouse, and it is the healthy mice of 18-22g to take weight, random to be grouped, every group 10 only into
Row experiment.
1, influence of the liquid fermentation coronoid process dissipate capsule bacterium functional complex to mouse immune organ weight
Each dosage group mouse continuous gavage was removed on the the 10th, 12 day to liquid fermentation coronoid process dissipate capsule bacterium functional complex 10 days
Intraperitoneal injection of cyclophosphamide (50mg/kg) takes rear 1h when continuously taking to the 15th day in last respectively outside Normal group,
Win each group mouse thymus and spleen.Using thymus gland or the ratio between spleen weight (mg) and weight (g) as thymus gland or spleen index, test
As a result as shown in table 2 below.
Influence of the 2 liquid fermentation coronoid process dissipate capsule bacterium functional complex of table to mouse immune organ weight
The result shows that compared with model group, mouse thymus index and the spleen index of high dose group are significantly increased (P<
0.01)。
2, liquid fermentation coronoid process dissipate capsule bacterium functional complex forms (HC to mice serum half hemolysis element50) influence
Each dosage group animal continuous gavage 30d takes blood, detaches serum, observes hemagglutination degree by Hemagglutination Method, calculates
Antibody product, the results are shown in Table 3.
3 functional complex of table is to mice serum half hemolysis element (HC50) formed influence
3, liquid fermentation coronoid process dissipate capsule bacterium functional complex swallows Turnover of Mouse Peritoneal Macrophages the influence of chicken red blood cell
Each dosage group animal continuous gavage 30d measures macrophage phagocytic function by half intracorporal method, and the results are shown in Table 4.
4 functional complex of table swallows Turnover of Mouse Peritoneal Macrophages the phagocytic rate of chicken red blood cell and the influence of phagocytic index
The above results of animal confirms that functional complex prepared by the present invention has reducing blood lipid immune with enhancing mouse
The double effects of power.
In conclusion invention is by preparing tea leaching liquor, preparing that fermentation culture, to prepare coronoid process dissipate capsule bacterium outstanding
Liquid, coronoid process dissipate capsule bacterium liquid fermentation and five steps of function and service object are produced, by ordinary tea leaves and matrimony vine, jujube, American Ginseng etc.
Pure natural substance prepares fermentation culture as additive, and coronoid process dissipate capsule bacterium, which is fermented, using the culture solution is made functional compound
Object, the compound taste faint scent, contained nutritional ingredient is various, is free of any food additives, and has both immunological regulation and drop
The double effects of blood fat.
In addition, the description for being related to " first ", " second " etc. in the present invention is used for description purposes only, and should not be understood as referring to
Show or imply its relative importance or implicitly indicates the quantity of indicated technical characteristic." first ", " are defined as a result,
Two " feature can explicitly or implicitly include at least one of the features.
Technical solution between each embodiment can be combined with each other, but must be with those of ordinary skill in the art's energy
It is enough realize based on, when the knot that conflicting or cannot achieve when will be understood that this technical solution occurs in the combination of technical solution
Conjunction is not present, also not the present invention claims protection domain within.
Claims (10)
1. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method, it is characterised in that：Include the following steps
Step 1：Prepare tea leaching liquor
Tealeaves and active additive, water are added in water：Tealeaves：The weight ratio of active additive is 100: 4-8: 0.5-3, in perseverance
20-60min is extracted under the conditions of warm 60-120 DEG C, is filtered to remove tea grounds up to tea leaching liquor；
Step 2：Prepare fermentation culture
The ratio mixed preparing for being 100: 4-8 in volume mass ratio by tea leaching liquor made from step 1 and carbon source nutriment,
The pH value of solution of configuration is 5.0-5.5, is then 115-121 DEG C in temperature condition, pressure continues under the conditions of 0.1-0.15MPa
20-30min sterilize up to fermentation culture；
Step 3：Prepare coronoid process dissipate capsule bacterium suspension
The strain of coronoid process dissipate capsule bacterium is coated on PDA agar mediums, under 28-30 DEG C of constant temperature, culture 4-6 days, so
Afterwards toward after being added 5-10ml sterile waters on solid medium, coronoid process dissipate capsule bacterium spore is scraped and is placed in the container equipped with sterile water
In, then coronoid process dissipate capsule bacterium spore suspension pours into suspension in oscillation container in sterile water upper surface, be placed in rotating speed and be
The shaking table of 150-300r/min vibrates 0.5-1h, is made a concentration of 5 × 108-9×108Cfu/mL eurotium cristatum spore suspensions；
Step 4：Coronoid process dissipate capsule bacterium liquid fermentation
By eurotium cristatum spore suspension made from step 3, the nothing made from step 2 is accessed according to the inoculum concentration of 5%-8%
In bacteria culture fluid, setting fermentation parameter is respectively：Rotating speed 100-500r/min, pH value 5.0-5.5, dissolved oxygen 20%-40%, temperature
28-30 DEG C of degree cultivates 120-168h, stops fermentation when zymotic fluid color is not further added by red gorgeous transparent and hyphae length；
Step 5：Produce function and service object
Collect and the zymotic fluid of the gained of concentration step four, remove moisture removal, detection wherein coronoid process dissipate capsule bacterium viable count not less than 1 ×
103Cfu/g is to get function and service object.
2. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as described in claim 1, it is characterised in that：Described
Active additive in step 1 is that matrimony vine or one or more of jujube or American Ginseng mix.
3. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as described in claim 1, it is characterised in that：Described
Carbon source nutriment is sucrose or glucose.
4. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as described in claim 1, it is characterised in that：Described
Zymotic fluid in step 4 is to be concentrated zymotic fluid using butterfly centrifugal machine.
5. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as described in claim 1, it is characterised in that：Described
Step 4 is concentrated into the 1/3-1/2 of original volume.
6. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as described in claim 1, it is characterised in that：Described
Tealeaves is the composition of black tea or one or more of green tea or black tea tea.
7. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound preparation method as described in claim 1, it is characterised in that：Described
Fermentation in step 2 is by the way of oxygen consumption fermentation.
8. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound is dissipated by a kind of coronoid process as described in any one of claim 1-7
Capsule bacterium Fermentation Function compound preparation method is made.
9. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound as claimed in claim 8, it is characterised in that：The functionality is multiple
It is solid pharmaceutical preparation, liquid preparation and gel preparation to close dosage form made of object, and wherein solid pharmaceutical preparation is tablet or pulvis or capsule
Or pill or tincture or granule, liquid preparation are suspension or emulsion.
10. a kind of coronoid process dissipate capsule bacterium Fermentation Function compound answering in drink or functional food as claimed in claim 8
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810632932.6A CN108771242A (en) | 2018-06-20 | 2018-06-20 | A kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810632932.6A CN108771242A (en) | 2018-06-20 | 2018-06-20 | A kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108771242A true CN108771242A (en) | 2018-11-09 |
Family
ID=64025275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810632932.6A Pending CN108771242A (en) | 2018-06-20 | 2018-06-20 | A kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108771242A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110591925A (en) * | 2019-09-06 | 2019-12-20 | 青岛中科星熠高新技术研究院有限公司 | Eurotium cristatum production fermentation method |
| CN111109604A (en) * | 2020-03-11 | 2020-05-08 | 深圳市清生元生物技术股份有限公司 | A fructus Lycii fermented product with antioxidant activity and its preparation method |
| CN111280353A (en) * | 2020-01-22 | 2020-06-16 | 湖南省茶业集团股份有限公司 | Preparation method of eurotium cristatum fermented bitter gourd juice |
| CN111803533A (en) * | 2020-07-01 | 2020-10-23 | 陕西巨子生物技术有限公司 | Composition for reducing blood sugar and blood fat, preparation method and application thereof |
| CN111961142A (en) * | 2020-08-11 | 2020-11-20 | 陕西巨子生物技术有限公司 | Preparation method of eurotium cristatum spore polysaccharide component |
| CN113142276A (en) * | 2021-04-27 | 2021-07-23 | 陕西巨子特医食品有限公司 | Health-care biscuit and preparation method thereof |
| CN114431312A (en) * | 2022-01-24 | 2022-05-06 | 浙江欣诺医药有限公司 | Black tea active powder and solid beverage thereof |
| CN114958621A (en) * | 2022-06-13 | 2022-08-30 | 陕西科技大学 | Method for culturing eurotium cristatum by using different tea water |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249112A (en) * | 2008-03-21 | 2008-08-27 | 贺志弘 | Fat-reducing products containing black tea Eurotium Cristatum and preparation thereof |
| CN103666933A (en) * | 2013-12-31 | 2014-03-26 | 广西国茗金花茶科技有限公司 | Golden camellia fermentation wine making method |
| CN103999946A (en) * | 2014-05-16 | 2014-08-27 | 中南林业科技大学 | Eurotium cristatum fermentation type rice milk health care beverage and preparation method thereof |
| CN104886304A (en) * | 2015-04-07 | 2015-09-09 | 安徽农业大学 | A preparation method of instant high-aroma dark tea |
| CN106889271A (en) * | 2017-03-27 | 2017-06-27 | 蔚长飞 | A kind of Novel medlar tea |
| CN107258971A (en) * | 2017-05-24 | 2017-10-20 | 天津瑞特医疗保健用品开发有限公司 | With alopecia-stopping, black hair, hair tonic, the compound black tea sugar of face-nursing function and its preparation method and application |
| CN107455520A (en) * | 2017-10-10 | 2017-12-12 | 南京农业大学 | A kind of preparation method of green tea beverage |
| CN107712173A (en) * | 2017-11-28 | 2018-02-23 | 申国庆 | It is a kind of that the method for preparing instant dark tea is combined with artificial infection and liquid state fermentation |
-
2018
- 2018-06-20 CN CN201810632932.6A patent/CN108771242A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249112A (en) * | 2008-03-21 | 2008-08-27 | 贺志弘 | Fat-reducing products containing black tea Eurotium Cristatum and preparation thereof |
| CN103666933A (en) * | 2013-12-31 | 2014-03-26 | 广西国茗金花茶科技有限公司 | Golden camellia fermentation wine making method |
| CN103999946A (en) * | 2014-05-16 | 2014-08-27 | 中南林业科技大学 | Eurotium cristatum fermentation type rice milk health care beverage and preparation method thereof |
| CN104886304A (en) * | 2015-04-07 | 2015-09-09 | 安徽农业大学 | A preparation method of instant high-aroma dark tea |
| CN106889271A (en) * | 2017-03-27 | 2017-06-27 | 蔚长飞 | A kind of Novel medlar tea |
| CN107258971A (en) * | 2017-05-24 | 2017-10-20 | 天津瑞特医疗保健用品开发有限公司 | With alopecia-stopping, black hair, hair tonic, the compound black tea sugar of face-nursing function and its preparation method and application |
| CN107455520A (en) * | 2017-10-10 | 2017-12-12 | 南京农业大学 | A kind of preparation method of green tea beverage |
| CN107712173A (en) * | 2017-11-28 | 2018-02-23 | 申国庆 | It is a kind of that the method for preparing instant dark tea is combined with artificial infection and liquid state fermentation |
Non-Patent Citations (3)
| Title |
|---|
| 王冰等: "冠突散囊菌的营养作用研究进展 ", 《饲料博览》 * |
| 黄彦等: "冠突散囊菌的研究与应用进展 ", 《生物加工过程》 * |
| 龚淑俐等: "冠突散囊菌胞外多糖含量测定及提取工艺研究 ", 《食品研究与开发》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110591925A (en) * | 2019-09-06 | 2019-12-20 | 青岛中科星熠高新技术研究院有限公司 | Eurotium cristatum production fermentation method |
| CN111280353A (en) * | 2020-01-22 | 2020-06-16 | 湖南省茶业集团股份有限公司 | Preparation method of eurotium cristatum fermented bitter gourd juice |
| CN111109604A (en) * | 2020-03-11 | 2020-05-08 | 深圳市清生元生物技术股份有限公司 | A fructus Lycii fermented product with antioxidant activity and its preparation method |
| CN111803533A (en) * | 2020-07-01 | 2020-10-23 | 陕西巨子生物技术有限公司 | Composition for reducing blood sugar and blood fat, preparation method and application thereof |
| CN111961142A (en) * | 2020-08-11 | 2020-11-20 | 陕西巨子生物技术有限公司 | Preparation method of eurotium cristatum spore polysaccharide component |
| CN111961142B (en) * | 2020-08-11 | 2022-03-22 | 陕西巨子生物技术有限公司 | Preparation method of eurotium cristatum spore polysaccharide component |
| CN113142276A (en) * | 2021-04-27 | 2021-07-23 | 陕西巨子特医食品有限公司 | Health-care biscuit and preparation method thereof |
| CN114431312A (en) * | 2022-01-24 | 2022-05-06 | 浙江欣诺医药有限公司 | Black tea active powder and solid beverage thereof |
| CN114958621A (en) * | 2022-06-13 | 2022-08-30 | 陕西科技大学 | Method for culturing eurotium cristatum by using different tea water |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108771242A (en) | A kind of coronoid process dissipate capsule bacterium Fermentation Function compound and its preparation method and application | |
| CN101965969B (en) | Health-care food composition with anti-fatigue and immunity-improving functions and preparation method and application thereof | |
| CN102907514B (en) | Preparation method of golden flower fungus fermented tea tree mushroom drink | |
| CN104982928B (en) | A kind of japanese yew fruit health care ferment and preparation method thereof | |
| CN103636946B (en) | Preparation method and application of Chinese herbal medicine immunological enhancer for finless eel | |
| CN103141702B (en) | Chinese herb extract feed additive capable of effectively preventing and treating porcine epizootic diarrhea | |
| CN101696444B (en) | Polypeptide extract as well as preparation method and application thereof | |
| CN108308468A (en) | A kind of dendrobium candidum enzyme beverage and preparation method thereof with defaecation, stomach-nourishing function | |
| CN102578556A (en) | Rainbow conk chewable tablet and preparation method thereof | |
| WO2020177389A1 (en) | Ergothioneine-containing hericium erinaceus health product formulation and preparation method therefor | |
| CN107267403A (en) | Culture medium, hickory chick compound bacteria filament and the preparation method of Morchella esculenta (L.) Pers mycelium | |
| CN103299824B (en) | Method for preparing phellinus igniarius sclertium from fresh, tender and sweet corn | |
| CN103651804A (en) | Prebiotic and probiotic added milk tablet based on homology of medicine and food | |
| CN104921238A (en) | Toxin-removing and beauty-maintaining health-care beverage and preparation method thereof | |
| CN104522750A (en) | Alga healthcare food | |
| CN106728083A (en) | Spina date seed Poria cocos common fermentation product and its preparation method and application | |
| CN104522165B (en) | Yoghourt of Lactobacillus casei N1115 hypolipemic functions and preparation method thereof | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN101228953B (en) | Organic Se-rich lucid ganoderma healthy product and preparing method thereof | |
| CN107279980A (en) | A kind of jujube ferment | |
| CN103865816A (en) | Yeast powder rich in selenium and germanium | |
| CN116042470A (en) | Traditional Chinese medicine fermentation by using novel rhamnose cheese bacillus strain and application thereof | |
| CN109007226A (en) | A kind of Astaxanthin In Haematococcus Pluvialis pectase pressed candy and preparation method thereof | |
| CN1784997A (en) | Method for preparing sour milk contg. composite micron pollen pini and konjak for reducing-weight and lowering-blood sugar | |
| CN107568506A (en) | Fresh water fish feed and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181109 |